Chugai Pharmaceutical Co., Ltd.

The Roche alliance creates a structural export and royalty revenue base that has supported 9 consecutive years of core profit growth, including through the 2020 COVID recession. FY2025 core revenue of ¥1,257.9 billion exceeded the initial guidance of ¥1,190.0 billion by 5.7%, continuing a multi-year pattern of at-or-above guidance delivery.

Revenue spans oncology, hematology, immunology, and ophthalmology with no single therapeutic area holding an overwhelming share; Hemlibra and Actemra are likely the two largest contributors. The portfolio avoids extreme single-product concentration but remains entirely within specialty biologics, limiting diversification across genuinely uncorrelated end markets.

Japan domestic sales were ¥472.4 billion (roughly 38% of FY2025 revenue), while overseas revenues reached ¥605.4 billion (roughly 48%), representing exports to Roche for global distribution rather than independent market presence in multiple regions. Revenue exposure beyond Japan is real but flows almost entirely through one commercial partner.

Core operating margin reached 49.5% in FY2025, rising materially over the prior several years as export volumes for Hemlibra and Actemra grew against a relatively fixed research and manufacturing cost base. The Roche commercialization arrangement amplifies scale without requiring Chugai to build proportional global commercial infrastructure.

The bilateral Roche alliance establishes long-term export and licensing arrangements that function as structurally recurring revenue, supplemented by royalty streams tied to global product sales. Japan domestic revenues come from prescription specialty biologics for serious chronic conditions including hemophilia, rheumatoid arthritis, and cancer, with high treatment adherence.